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IFNγ: Issuing macrophages a license to kill
T cells tell macrophages when to start making the toxic soup of lysosomal 
enzymes, reactive oxygen species, and nitric oxide that destroys intracellular 
pathogens. In 1983, Carl Nathan proved that this start signal comes in the 
form of the secreted cytokine IFN𝗄.
In 1962, George Mackaness showed 
that T cells, once activated by invading 
microbes, instruct macrophages to kill 
intracellular pathogens (1). But exactly 
how T cells turned the passive macro-
phages into aggressive killers remained 
a mystery for more than a decade.
The elusive eluate
Nathan, as an oncology fellow, knew 
well that white blood cells fought 
infections. “This was an experiment 
repeated in front of us all the time,” he 
says: chemotherapy lowered his patients’ 
white blood cells and increased their 
risk of infections.
One link in that infection-fighting 
chain was T cell activation of macro-
phages. Mackaness had shown that 
macrophage activation did not depend 
on direct contact with T cells (1), 
suggesting the possibility of a secreted 
factor. When Nathan tested the super-
natant from activated T cells, he saw 
that it did indeed induce macrophage 
activation (2).
The race was on to purify and iden-
tify the mystery factor. Nathan got a 
rough idea of the molecular weight (3), 
but that was “the best anyone could 
do,” he says. Protein separation methods 
were primitive, and cloned proteins 
and monoclonal antibodies would only 
become available a decade later. Henry 
Murray, one of Nathan’s collaborators, 
sums up the feeling of frustration: “We 
were all nibbling at the edges of the 
same problem.”
Nathan therefore changed tack to 
take a closer look at the activated 
macro  phages. Short-lived neutrophils 
were known to produce hydrogen per-
oxide, and Nathan found the same was 
true of longer-lived activated macro-
phages (4). Unlike previous signs of macro-
phage activation—increased spreading, 
phagocytosis, and glucose metabolism—
this so-called “respiratory burst”  correlated 
with the cells’ ability to kill intracellular 
parasites (4).
Back on track
Meanwhile, candidate macrophage 
activators were in the news. IFNα had 
been on the cover of Time magazine, 
and recombinant murine IFNγ was 
found to induce macrophages to kill 
tumor cells (5). Nathan, now a faculty 
member in Zanvil Cohn’s “macro-
phage factory” at Rockefeller University 
(New York, NY), thought IFNγ might 
also activate macrophages to kill intra-
cellular parasites.
Consistent with this idea, IFNγ 
was made by antigen-stimulated T 
cells and was associated with defense 
from infection. Now the respiratory 
burst gave Nathan an assay, Berish 
Rubin (down the street at the New 
York Blood Center) supplied an IFNγ 
monoclonal antibody, and a phone call 
to Genentech yielded recombinant 
IFNγ. In a seminal paper published in 
The Journal of Experimental Medicine in 
1983, Nathan was thus able to show 
that depleting IFNγ from unpurified 
T cell supernatants decreased the respi-
ratory burst activity and the killing of 
intracellular protozoa in human macro-
phages. Adding back recombinant 
IFNγ into this mix restored macro-
phage activation (6).
The clues were there, says Nathan, 
but to be honest “I would have tried 
any cytokine that was purified to homo-
geneity. I had an assay, a hunch, a 
history of purifying proteins that did 
this, and the serendipity of meeting 
with people nearby who had the 
antibody.”
Nathan next showed that IFNγ 
worked in people. Injecting recombi-
nant IFNγ directly into cutaneous 
lesions of lepromatous leprosy patients 
induced macrophage infiltration, hy-
drogen peroxide production, and 
  killing of the causative pathogen, 
  Mycobacterium leprae (7). In the 1990s, 
the macrophages of children with 
IFNγ receptor deficiencies were 
shown to be defective in killing myco-
bacteria (8). Tracing the pathway from 
T cells to macrophages to bacteria 
started, for Nathan, in 1967, and he 
says “we still haven’t finished making 
the molecular links.”
REFERENCES
 1. Mackaness, G.B. 1962. J. Exp. Med. 116:
381–406.
 2. Nathan, C.F., et al. 1971. J. Exp. Med. 133:
1356–1376.
 3.  Nathan, C.F., et al. 1973. J. Exp. Med. 137:
275–290.
 4. Nathan, C.F., and Root, R.K. 1977. J. Exp. 
Med. 146:1648–1662.
 5. Pace, J.L., et al. 1983. J. Immunol. 130:
2011–2013.
 6.  Nathan, C.F., et al. 1983. J. Exp. Med. 158:
670–689.
 7. Nathan, C.F., et al. 1986. N. Engl. J. Med. 
315:6–15.
 8.  Jouanguy, E., et al. 1997. J. Clin. Invest. 100:
2658–2664.
Text by Hema Bashyam
JEM News Editor; hbashyam@rockefeller.edu
Carl Nathan